RecruitingNot ApplicableNCT06962033

PRIDE III Prison Interventions and HIV Prevention Collaboration

Sponsor

Yale University

Enrollment

300 participants

Start Date

Nov 5, 2024

Study Type

INTERVENTIONAL

Conditions

Opioid Use HIV

Summary

The primary objective of this research project is to identify barriers to scale-up of Opioid Agonist Therapy (OAT) in the justice systems (prisons and probation) in Tajikistan, Kyrgyzstan, Moldova, and Georgia, and establish a NIATx learning collaborative to scale-up OAT, and analyze scale-up utilizing latent class growth analyses in people who inject drugs (PWID).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at ways to improve HIV prevention in prisons and probation settings by expanding access to opioid agonist therapy (OAT) — a treatment that reduces opioid use and drug injection, which lowers HIV transmission risk. The study will survey providers, officers, and people on probation, and run focus groups to understand barriers and solutions. **You may be eligible if...** - You are 18 or older - AND one of the following: - You are a healthcare provider delivering OAT at a probation site - You are currently on probation and have injected opioids - You are a probation or prison officer currently working at a probation site (with 3+ months of experience and working within 25 km of an OAT site, for focus groups) **You may NOT be eligible if...** - You do not meet any of the above roles or criteria Talk to your doctor or legal/healthcare contact to see if this study is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.